Cysteine-Rich secretory protein-3 (CRISP3) is strongly Up-Regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Ribeiro, Franclim R ^a,c,d   Paulo, Paula ^a,c,d   Costa, Vera L ^a,c,d   Barros Silva, João D ^a   Ramalho Carvalho, João ^a   Jerónimo, Carmen ^a,b   Henrique, Rui ^a,b   Lind, Guro E ^c,d   Skotheim, Rolf I ^c,d   Lothe, Ragnhild A ^c,d   Teixeira, Manuel R ^a,b,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH SECRETORY PROTEIN 3; MEMBRANE PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; CRISP3 PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; SALIVA PROTEIN; SEMINAL PLASMA PROTEIN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN OVEREXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TMPRSS2 ERG FUSION GENE; UPREGULATION; CASE CONTROL STUDY; COMPARATIVE STUDY; DNA MICROARRAY; ENZYME IMMUNOASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALIVARY PROTEINS AND PEPTIDES; SEMINAL PLASMA PROTEINS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79960632568     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022317     Document Type: Article

References (39)

1. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
2. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, et al. (2006) TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66: 3396-3400.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
4. Lin B, Ferguson C, White JT, Wang S, Vessella R, et al. (1999) Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 59: 4180-4184.
5. Clark JP, Cooper CS, (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6: 429-439.
6. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, et al. (2006) TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8: 826-832.
7. Foos G, Hauser CA, (2000) Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness. Oncogene 19: 5507-5516.
8. Hsu T, Trojanowska M, Watson DK, (2004) Ets proteins in biological control and cancer. JCell Biochem 91: 896-903.
9. Sementchenko VI, Watson DK, (2000) Ets target genes: past, present and future. Oncogene 19: 6533-6548.
10. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, et al. (2006) TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66: 10242-10246.
11. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
12. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, et al. (2007) Integrative molecular concept modeling of prostate cancer progression. NatGenet 39: 41-51.
13. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
14. Ribeiro FR, Henrique R, Martins AT, Jeronimo C, Teixeira MR, (2007) Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol 52: 116-125.
15. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, et al. (2007) Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. ModPathol 20: 538-544.
16. Schmittgen TD, Livak KJ, (2008) Analyzing real-time PCR data by the comparative C(T) method. NatProtoc 3: 1101-1108.
17. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, et al. (2008) Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. JNatlCancer Inst 100: 815-825.
18. Sandelin A, Wasserman WW, Lenhard B, (2004) ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res 32: W249-252.
19. Carvalho JR, Filipe L, Costa VL, Ribeiro FR, Martins AT, et al. (2010) Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Apoptosis 15: 956-965.
20. Wilson CL, Miller CJ, (2005) Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis. Bioinformatics 21: 3683-3685.
21. Jhavar S, Reid A, Clark J, Kote-Jarai Z, Christmas T, et al. (2008) Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J Mol Diagn 10: 50-57.
22. Gibbs GM, Roelants K, O'Bryan MK, (2008) The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins-roles in reproduction, cancer, and immune defense. Endocr Rev 29: 865-897.
23. Brooks DE, (1987) Androgen-regulated epididymal secretory proteins associated with post-testicular sperm development. Ann N Y Acad Sci 513: 179-194.
24. Haendler B, Kratzschmar J, Theuring F, Schleuning WD, (1993) Transcripts for cysteine-rich secretory protein-1 (CRISP-1; DE/AEG) and the novel related CRISP-3 are expressed under androgen control in the mouse salivary gland. Endocrinology 133: 192-198.
25. Kjeldsen L, (1995) Gelatinase granules in human neutrophils. Eur J Haematol Suppl 56: 1-30.
26. Kratzschmar J, Haendler B, Eberspaecher U, Roosterman D, Donner P, et al. (1996) The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3. Eur J Biochem 236: 827-836.
27. Udby L, Bjartell A, Malm J, Egesten A, Lundwall A, et al. (2005) Characterization and localization of cysteine-rich secretory protein 3 (CRISP-3) in the human male reproductive tract. J Androl 26: 333-342.
28. Udby L, Calafat J, Sorensen OE, Borregaard N, Kjeldsen L, (2002) Identification of human cysteine-rich secretory protein 3 (CRISP-3) as a matrix protein in a subset of peroxidase-negative granules of neutrophils and in the granules of eosinophils. J Leukoc Biol 72: 462-469.
29. Udby L, Cowland JB, Johnsen AH, Sorensen OE, Borregaard N, et al. (2002) An ELISA for SGP28/CRISP-3, a cysteine-rich secretory protein in human neutrophils, plasma, and exocrine secretions. J Immunol Methods 263: 43-55.
30. Asmann YW, Kosari F, Wang K, Cheville JC, Vasmatzis G, (2002) Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res 62: 3308-3314.
31. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, et al. (2002) Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 160: 2169-2180.
32. Bjartell A, Johansson R, Bjork T, Gadaleanu V, Lundwall A, et al. (2006) Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 66: 591-603.
33. Kosari F, Asmann YW, Cheville JC, Vasmatzis G, (2002) Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 11: 1419-1426.
34. Udby L, Lundwall A, Johnsen AH, Fernlund P, Valtonen-Andre C, et al. (2005) beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun 333: 555-561.
35. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, et al. (2007) Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 13: 4130-4138.
36. Barros-Silva JD, Ribeiro FR, Rodrigues A, Cruz R, Martins AT, et al. (2011) Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes Cancer 50: 662-671.
37. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624.
38. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, et al. (2008) TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis. ClinCancer Res 14: 3395-3400.
39. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, et al. (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13: 519-528.